ARCHIVES

DSMB Recommends Discontinuing Phase III Perifosine Combination Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

NCI SBIR Offers $10 million in 10 Awards

February 18, 2011

A Special Report: Language With A Purpose–von Eschenbach’s Four Years at NCI.

May 19, 2006

European Commission Approves Subcutaneous Rituximab

March 28, 2014

NIH Panel Urges Wider Treatment of Hepatitis C

June 14, 2002

Ford Gets Temporary Funds Bill; House Committee Demands More Positions for NCI

June 27, 1975

In This Issue: Congressional Testimony On NIH, NCI Appropriations, FDA Reform

May 9, 1997